Patients’ Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study
Martin J. Connor(Imperial College Healthcare NHS Trust), Verity Watson(University of Aberdeen), Angus Robinson(Royal Sussex County Hospital), Narayanan Srihari(Shrewsbury and Telford Hospital NHS Trust), Peter Ostler(Luton and Dunstable Hospital), Gail Horan(Queen Elizabeth Hospital King's Lynn NHS Foundation Trust), Natalia Klimowska‐Nassar(Imperial College London), Mathias Winkler(National Health Service), Tim Dudderidge(University Hospital Southampton NHS Foundation Trust), Sangeeta Paisey(Hampshire Hospitals NHS Foundation Trust), Pasquale F. Innominato(Betsi Cadwaladr University Health Board), Johanna Sukumar(Imperial College London), Naveed Sarwar(Imperial College Healthcare NHS Trust), Sanjeev Madaan(Dartford And Gravesham NHS Trust), Stephen Mangar(Imperial College Healthcare NHS Trust), Vincent Khoo(The University of Texas MD Anderson Cancer Center), Hangjian Wu(University of Aberdeen), Mesfin G. Genie(Duke University), Diletta Bianchini(Royal Marsden NHS Foundation Trust), Kamal Thippu Jayaprakash(Queen Elizabeth Hospital King's Lynn NHS Foundation Trust), Chee Leok Goh(Cornell University), Stuart McCracken(Newcastle University), Hashim U. Ahmed(National Health Service), Mohini Varughese(Musgrove Park Hospital), Mark Beresford(Royal United Hospital Bath NHS Trust)
Cited by 4
Related Papers
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
|The Lancet|2017|3.2k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Multiple newly identified loci associated with prostate cancer susceptibility
|Nature Genetics|2008|850